CA2846644C - Method of reducing exercise-induced joint pain in non-arthritic mammals - Google Patents

Method of reducing exercise-induced joint pain in non-arthritic mammals Download PDF

Info

Publication number
CA2846644C
CA2846644C CA2846644A CA2846644A CA2846644C CA 2846644 C CA2846644 C CA 2846644C CA 2846644 A CA2846644 A CA 2846644A CA 2846644 A CA2846644 A CA 2846644A CA 2846644 C CA2846644 C CA 2846644C
Authority
CA
Canada
Prior art keywords
collagen
pain
undenatured type
knee
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2846644A
Other languages
English (en)
French (fr)
Other versions
CA2846644A1 (en
Inventor
Paul Dijkstra
Francis C. Lau
James Lugo
Zainulabedin M. Saiyed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Greenwood LLC
Original Assignee
Interhealth Nutraceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interhealth Nutraceuticals Inc filed Critical Interhealth Nutraceuticals Inc
Publication of CA2846644A1 publication Critical patent/CA2846644A1/en
Application granted granted Critical
Publication of CA2846644C publication Critical patent/CA2846644C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2846644A 2013-10-24 2014-01-13 Method of reducing exercise-induced joint pain in non-arthritic mammals Active CA2846644C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895332P 2013-10-24 2013-10-24
US61/895,332 2013-10-24
PCT/US2014/011303 WO2015060888A1 (en) 2013-10-24 2014-01-13 Method of reducing exercise-induced joint pain in non-arthritic mammals

Publications (2)

Publication Number Publication Date
CA2846644A1 CA2846644A1 (en) 2015-07-13
CA2846644C true CA2846644C (en) 2018-05-01

Family

ID=51610711

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2846644A Active CA2846644C (en) 2013-10-24 2014-01-13 Method of reducing exercise-induced joint pain in non-arthritic mammals

Country Status (14)

Country Link
US (1) US9066926B2 (enExample)
KR (1) KR101664290B1 (enExample)
AR (1) AR095104A1 (enExample)
AU (1) AU2014202041B8 (enExample)
BR (1) BR112014011741A2 (enExample)
CA (1) CA2846644C (enExample)
CL (1) CL2014001281A1 (enExample)
CO (1) CO7020846A2 (enExample)
IN (1) IN2014DE00193A (enExample)
MX (1) MX347669B (enExample)
MY (1) MY180106A (enExample)
PH (1) PH12014501453A1 (enExample)
SG (1) SG11201403524RA (enExample)
WO (1) WO2015060888A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226513B2 (en) 2015-01-09 2019-03-12 Mark Terrell Smith Method and composition to prevent or improve symptoms of musculoskeletal distress degeneration
AU2017325823A1 (en) * 2016-09-16 2019-05-02 Boston Scientific Neuromodulation Corporation System for pain management using heart sounds
WO2018063912A1 (en) 2016-09-27 2018-04-05 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop pain management
AU2017335497B2 (en) 2016-09-27 2020-01-16 Boston Scientific Neuromodulation Corporation System for pain management using objective pain measure
US11793217B1 (en) 2016-10-04 2023-10-24 Lonza Greenwood Llc Method of manufacture and pasteurization of products containing undenatured collagen
US11850324B2 (en) 2016-10-12 2023-12-26 Advanced Biomatrix, Inc. Three-dimensional (3-D) printing inks made from natural extracellular matrix molecules
WO2018080887A1 (en) 2016-10-25 2018-05-03 Boston Scientific Neuromodulation Corporation System for pain management using baroreflex sensitivity
US10631777B2 (en) 2017-01-11 2020-04-28 Boston Scientific Neuromodulation Corporation Pain management based on functional measurements
US10729905B2 (en) 2017-01-11 2020-08-04 Boston Scientific Neuromodulation Corporation Pain management based on muscle tension measurements
US11089997B2 (en) 2017-01-11 2021-08-17 Boston Scientific Neuromodulation Corporation Patient-specific calibration of pain quantification
EP3568069B1 (en) 2017-01-11 2021-04-28 Boston Scientific Neuromodulation Corporation Pain management based on brain activity monitoring
US10926091B2 (en) 2017-01-11 2021-02-23 Boston Scientific Neuromodulation Corporation Pain management based on emotional expression measurements
US10631776B2 (en) 2017-01-11 2020-04-28 Boston Scientific Neuromodulation Corporation Pain management based on respiration-mediated heart rates
US10960210B2 (en) 2017-02-10 2021-03-30 Boston Scientific Neuromodulation Corporation Method and apparatus for pain management with sleep detection
CN106713191B (zh) * 2017-02-28 2020-09-08 西安电子科技大学 一种多级搜索sage方法
CN107048412A (zh) * 2017-04-26 2017-08-18 北京盛美诺生物技术有限公司 一种含有ⅱ型胶原蛋白的咀嚼型产品
AU2018304079B2 (en) 2017-07-18 2020-12-03 Boston Scientific Neuromodulation Corporation Sensor-based pain management systems and methods
US20190054152A1 (en) * 2017-08-21 2019-02-21 Lonza Inc. Composition and Nutritional Supplement Made Therefrom
US20190060415A1 (en) * 2017-08-31 2019-02-28 Lonza Inc. Health promoting composition and methods of use supplement
IT201700111939A1 (it) * 2017-10-05 2019-04-05 Jointherapeutics S R L Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
CA3106630A1 (en) * 2018-07-16 2020-01-23 Lonza Consumer Health Inc. Collagen and cell matter supplement and method for administering same
WO2021016665A1 (en) * 2019-07-30 2021-02-04 Atp Institute Pty Ltd A gummy composition
WO2021067452A1 (en) * 2019-09-30 2021-04-08 Lonza Consumer Health Inc. Cannabinoid product for improving musculoskeletal health
BR112022014911A2 (pt) 2020-01-29 2022-09-20 Lonza Consumer Health Inc Composição de saúde articular e uso da mesma em mamíferos saudáveis
CN115379762A (zh) 2020-03-03 2022-11-22 龙沙格林伍德有限公司 食物和饮料应用中的非变性ii型胶原蛋白和其用途
WO2021195068A1 (en) 2020-03-24 2021-09-30 Lonza Consumer Health Inc. Undenatured type ii collagen in animal food and treats
EP4146251A1 (en) 2020-06-12 2023-03-15 Lonza Greenwood LLC Undenatured type ii collagen as a supplement for improved endurance, lipid metabolism, and oxidative stress
WO2022040026A1 (en) * 2020-08-19 2022-02-24 Lonza Consumer Health Inc. Method for improving inflammation, joint health, joint mobility, and joint comfort in healthy mammals
CN115120618B (zh) * 2021-03-23 2024-01-26 安徽盛美诺生物技术有限公司 具有改善免疫应答作用的软骨提取物、其制备方法及其用途
KR20240101672A (ko) * 2021-11-12 2024-07-02 론자 그린우드 엘엘씨 골격 관절의 치료 방법 및 이의 조성물 및 용도
KR102771944B1 (ko) * 2023-09-25 2025-02-26 (주)온오퍼 고함량 액티브 성분을 갖는 반려동물용 츄 형태 영양제
WO2026006443A1 (en) * 2024-06-25 2026-01-02 Viscus Biologics, Llc Nutritional joint health supplement compositions and methods for making and using same
KR102923372B1 (ko) 2024-07-04 2026-02-05 씨엔에이바이오텍(주) 비변성 ⅱ형 콜라겐 제조방법 및 그의 제조방법에 따라 제조되는 비변성 ⅱ형 콜라겐

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
AU2800492A (en) 1991-11-08 1993-06-07 Gunilla Lofgren Nisser Partially occluded contact lens for treating visual and/or brain disorder
US5645851A (en) 1994-02-28 1997-07-08 Moore; Eugene R. Product for alleviating the symptons of arthritis in mammals
US5637321A (en) 1994-02-28 1997-06-10 Moore; Eugene R. Method for preparing animal tissue for use in alleviating the symptoms of arthritis in mammals
US5529786A (en) 1994-02-28 1996-06-25 Moore; Eugene R. Process and product for treatment of rheumatoid arthritis
US6162787A (en) 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
US6372794B1 (en) * 1999-08-26 2002-04-16 Marcel E. Nimni Method for alleviating arthritis in mammals
US20020086070A1 (en) 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
US7083820B2 (en) 2000-09-29 2006-08-01 Schilling Marvin L Method for producing biologically active products
JP2003048850A (ja) 2001-06-01 2003-02-21 Nippon Meat Packers Inc 関節傷害治療剤及び機能性食品
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
FR2900155B1 (fr) * 2006-04-21 2008-06-27 Diana Naturals Sa Hydrolisat de cartilage aviaire, procede d'obtention et utilisations
US20100215731A1 (en) 2009-02-20 2010-08-26 Maastricht University Method for improving cartilage repair and/or preventing cartilage degeneration in a joint
US20110218151A1 (en) 2010-03-04 2011-09-08 Joar Opheim Substances for promoting healthy joint function comprising omega-3 polyunsaturated fatty acids or drivatives thereof, undenatured type ii collagen and, optionally, glucosamine sulfate
CN101822684B (zh) 2010-05-27 2012-08-15 江苏江山制药有限公司 用于防治骨关节痛的复方组合制剂及其制备方法
US20120294898A1 (en) 2011-05-19 2012-11-22 Warsaw Orthopedic, Inc. Injectable dbm for soft tissue repair
CN102423487B (zh) 2011-12-23 2014-04-16 内蒙古伊利实业集团股份有限公司 一种骨关节保健组合物及其应用
CN103203012A (zh) 2012-01-12 2013-07-17 深圳市麦金利实业有限公司 关节保健品

Also Published As

Publication number Publication date
AU2014202041B8 (en) 2020-04-02
MX2014002934A (es) 2015-09-21
AR095104A1 (es) 2015-09-30
CL2014001281A1 (es) 2015-10-30
WO2015060888A1 (en) 2015-04-30
SG11201403524RA (en) 2015-05-28
US20150119335A1 (en) 2015-04-30
PH12014501453B1 (en) 2015-01-21
KR20150059132A (ko) 2015-05-29
IN2014DE00193A (enExample) 2015-05-01
MX347669B (es) 2017-05-08
MY180106A (en) 2020-11-23
AU2014202041A1 (en) 2015-05-14
PH12014501453A1 (en) 2015-01-21
CO7020846A2 (es) 2014-08-11
US9066926B2 (en) 2015-06-30
BR112014011741A2 (pt) 2017-05-30
CA2846644A1 (en) 2015-07-13
AU2014202041B2 (en) 2019-11-28
KR101664290B1 (ko) 2016-10-11

Similar Documents

Publication Publication Date Title
AU2014202041B8 (en) Method of reducing exercise-induced joint pain in non-arthritic mammals
Rémond et al. Understanding the gastrointestinal tract of the elderly to develop dietary solutions that prevent malnutrition
Canani et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow's milk allergy: 3-year randomized controlled trial
McDougall et al. Effects of a very low-fat, vegan diet in subjects with rheumatoid arthritis
Kim et al. Hair zinc levels and the efficacy of oral zinc supplementation in children with atopic dermatitis
JP6811170B2 (ja) 安全な嚥下を促進する嚥下障害者用栄養製品
JP2014506254A (ja) β−ヒドロキシ−β−メチルブチレートを用いる廃用期間後の筋肉回復を促進させるための方法
JP2019518744A (ja) 運動障害を治療又は予防するための栄養組成物
CN103596589A (zh) 花生过敏症的治疗
Poluektov Sleep and immunity
ES2995086T3 (en) Gastrointestinal health composition
Umborowati et al. Lactiplantibacillus plantarum IS-10506 supplementation improves clinical outcome and immunology markers in psoriasis vulgaris patients: a randomized controlled trial
TW202114543A (zh) 誘導飽足感之方法
JP2006077016A (ja) オメガＧＡ−３脂肪酸を用いたＩｇＡ腎症の治療
JP6360172B2 (ja) チグリンアルデヒドを使用する組成物及び方法
US20230284668A1 (en) Method for Improving Inflammation, Joint Health, Joint Mobility, and Joint Comfort in Healthy Mammals
Weinstein The stress effect
JP2016525132A (ja) ｐ−アニスアルデヒドを使用する組成物及び方法
Alshihmani et al. Immunomodulatory Effects of Multi‐Strain Probiotic Capsules for Psoriatic Arthritis: A Pilot Double‐Blind Randomized Controlled Trial
CN119300849A (zh) 用于治疗或预防儿童特应性疾病的组合方法
Spinks et al. In vivo osteoinduction: Evaluating 2-beta coxatene as an immunoinductive compound and novel ingredient for joint support
Spinks et al. Clinical assessment of low-dose osteoinductive protein as a stand-alone regimen in self-reported osteoarthritis
US12208073B2 (en) Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
US20250367146A1 (en) Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for enhancing recovery from soft tissue trauma
Wilson et al. Complementary and Alternative Approaches I

Legal Events

Date Code Title Description
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241230

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241230

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241230

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251230

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251230